Thyrocare Technologies Ltd (THYROCARE) — shareholding pattern, promoter holding, financials and share price
About Thyrocare Technologies Ltd (THYROCARE)
Thyrocare Technologies Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as THYROCARE and on the BSE under scrip code 539871. Its ISIN is INE594H01019.
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
Thyrocare Technologies Limited is a leading Indian diagnostic company, primarily focused on providing affordable and quality diagnostic services across the country. With a vast network of authorized service providers and laboratories, it offers a wide range of tests, including preventive and wellness profiles under the 'Aarogyam' brand.
In recent developments, Thyrocare reported an 18% YoY growth in revenue and 38% YoY growth in EBITDA for Q3 FY26, showcasing strong financial performance and operational scale. Franchise revenue and partnership segments also showcased notable growth.
Listed peers in Healthcare Service Provider: Vijaya Diagnostic Centre Ltd, Metropolis Healthcare Ltd, Nephrocare Health Services Ltd, Krsnaa Diagnostics Ltd, Suraksha Diagnostic Ltd, One Global Service Provider Ltd.
Valuation & Returns
10 Jul 2026At ₹516 a share on 10 Jul 2026, Thyrocare Technologies Ltd (THYROCARE) was valued at a price-to-earnings ratio of 50.43x against an industry P/E of 61.73x and a price-to-book of 14.03x on a book value of ₹36.79 per share as of Mar 2026. Solomo computes return on equity of 27.81% and return on capital employed of 33.9% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 50.43x
- Industry P/E
- 61.73x
- P/B
- 14.03x
- EPS (TTM)
- ₹10.23
- Book value / share
- ₹36.79
- ROE
- 27.81%
- ROCE
- 33.9%
- ROA
- 21.79%
- Debt / equity
- 0.09x
- Dividend yield
- 6.78%
- EBITDA margin
- 33.08%
- 52-week range
- ₹342.55 – ₹578.05
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Thyrocare Technologies Ltd (THYROCARE) reported revenue of ₹829 crore, net profit of ₹163 crore and earnings per share of ₹10.24. That compares with revenue of ₹687 crore and net profit of ₹91 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹224 crore and net profit ₹49 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 589 | 527 | 572 | 687 | 829 |
| Net profit (₹ cr) | 176 | 64 | 69 | 91 | 163 |
| EPS (₹) | 11.1 | 4.06 | 4.45 | 5.76 | 10.24 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.21% | 10.30% | 16.76% | 20.61% |
| Profit growth | 13.75% | 4.44% | 37.72% | 79.45% |
| Stock price CAGR | 11% | 4% | 42% | 32% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 60.92% of Thyrocare Technologies Ltd (THYROCARE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.44% and domestic institutional investors (DII) hold 20.92%. Promoters have pledged 100% of their holding. Market capitalisation was ₹8,213 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2016.
Largest disclosed public shareholders in Jun 2026: Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund 5.99%, Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 5.57%, Hsbc Mutual Fund - Hsbc Midcap Fund 3.84%, Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Elss Tax Saver Fund 3.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 60.92% | 100% | 5.44% | 20.92% | 39.08% |
| Mar 2026 | 60.92% | 100% | 5.37% | 20.99% | 39.08% |
| Dec 2025 | 60.93% | 100% | 4.95% | 20.51% | 39.07% |
| Sep 2025 | 71.06% | 85.8% | 4.85% | 13.47% | 28.94% |
| Jun 2025 | 71.06% | 100% | 3.23% | 14.54% | 28.94% |
| Mar 2025 | 71.06% | 100% | 2.41% | 14.97% | 28.94% |
| Dec 2024 | 71.06% | 100% | 2.77% | 14.67% | 28.94% |
| Sep 2024 | 71.11% | 100% | 1.93% | 14.8% | 28.89% |